secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptevo Therapeutics Inc. (APVO)
CIK:        0001671584
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0000950170-25-042340
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Two additional AML patients achieve remission in Cohort 2 of RAINIER trial; 90% response rate
--------------------------------------------------------------------------------

- Two additional AML patients in Cohort 2 of RAINIER trial achieved remission within 30 days of treatment.
- Overall 9 of 10 frontline AML patients achieved remission with mipletamig + ven/aza triplet, vs 66% doublet benchmark.
- Complete remission rate (CR) of 70% with triplet outperforms 36% CR from Viale-A ven/aza only study.
- No cytokine release syndrome (CRS) observed in RAINIER trial to date; all remissions ongoing.
- Cohort 2 enrollment nearing completion; six patients planned at 18 mcg dose level.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025042340/0000950170-25-042340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1671584/000095017025042340/apvo-20250320.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-042340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer